The preliminary evaluation of p-NH consisting of all-D amino acids in AD animals demonstrates that it is promising as a clinical candidate drug, and also highlights the enormous potential of mirror image phage display technology in targeted tau therapy. Here, MAPT is linked to Alzheimer disease.